GlobeNewswire News Room·2025-06-18 22:30Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between March 7, 2024, and March 3, 2025, with a lead plaintiff deadline set for August 8, 2025 [1][2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, as well as the CONNECT2 study's suitability for FDA approval [4]. - It is claimed that these misrepresentations led to an overstatement of PGN-ED051's clinical, regulatory, and commercial prospects, resulting in investor damages when the truth was revealed [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3].